Table 2.
On-going clinical trials for patients with brain tumors.
| Protocol ID | Immunotherapeutic Strategy | Phase | Treatment Strategy(s) |
|---|---|---|---|
| NCT00002572 | CTL’s and IL-2 | I | Repeated allogeneic CTL/IL-2 brain infusions for recurrent brain tumors. |
| NCT00014573 | Chemotherapy/Stem Cell Transplantation/Interleukin-2 | II | Combining chemotherapy, stem cell transplantation and IL-2 for refractory or recurrent brain tumors. |
| NCT00047879 | Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas | II | Peginterferon alpha-2b (PEG-Intron) alone and together with thalidomide in patients with gliomas. |
| NCT00504660 | 6-TG, Capecitabine and Celecoxib with TMZ or CCNU | II | The combination of capecitabine, celecoxib with temozolomide or CCNU in the treatment of recurrent or progressive anaplastic glioma or GBM in patients who have failed previous treatments. |
| NCT01454596 | White Blood Cells With Anti-EGFR-III | I/II | Using anti-EGFR-expressing leukocytes for advanced gliomas. |
| NCT00331526 | Cellular Adoptive Immunotherapy | II | IL-2 stimulated adoptive transfer of leukocytes in patients with GBM. |
| NCT01235845 | Combined CK/DC Treatment | I/II | Dendritic cell-activated cytokine killer (CK) treatment combined with DCs following tumor resection and radiotherapy for malignant glioma. |
| NCT01081223 | TVAX | I/II | TVAX generates large numbers of ‘killer’ white blood cells ex vivo for adoptive transfer into recurrent glioma (stage IV) for tumor destruction. |
| NCT01144247 | Allo CTL Therapy | I | Using allogeneic (donor) CTLs to destroy brain tumors. |
| NCT01082926 | Modified CTL Adoptive Transfer | I | Using an allogeneic CD8+ T cell line modified to express the IL 13-Zetakine and HyTK and to be resistant to glucocorticoids, in combination with IL-2 for recurrent/ refractory malignant glioma. |
| NCT00626483 | Treg depletion | I/II | Using daclizumab (humanized anti-CD25α) in treating patients with newly diagnosed GBM and during TMZ-induced lymphopenia. |
| NCT00795457 | Peptide/Adjuvant Delivery | 0 | Utilizing HLA-A2-restricted glioma antigen-peptides in combination with poly-ICLC for adult grade II astrocytomas and oligo-astrocytomas. |
| NCT00002965 | Interferon alpha (IFN-α) | II | Using IFN-α in patients with recurrent unresectable meningiomas and malignant meningiomas. |
| NCT01171469 | DC Vaccination | I | Autologous dendritic cells (DCs) loaded with allogeneic brain tumor stem cells administered as a vaccination in children and adults with recurrent brain tumors. |
CTL: cytotoxic T lymphocyte (CD8+ T cell); IL-2: interleukin-2; 6-TG: 6-thioguanine; TMZ: temozolomide; CCNU: Lomustine; EGFR: epidermal growth factor; GBM: glioblastoma multiforme; CK: cytokine killer; DC: dendritic cell; TVAX: immunotherapy made by TVAX biomedical; poly-ICLC: carboxymethylcellulose, polyinosinic-polycytidylic acid, and poly-L-lysine double-stranded RNA; IFN: interferon.